Organic Active Ingredients TRIZ Cases

Tertiary amine bicyclic compounds selectively inhibit DGKα/ζ to boost T cell activation while limiting off-target kinase effects.

A cell-penetrating anti-DNA antibody boosts triplex and nuclease editing frequency while limiting off-target effects through RAD51 inhibition.

Anti-transferrin receptor AOCs improve cardiac cell uptake and suppress PRKAG2 mRNA, addressing the genetic driver of PRKAG2 cardiac syndrome.

Formoterol promotes erythroid differentiation and mitochondrial biogenesis to treat anemia when standard erythropoiesis therapies fall short.

Synthetic TLR4 agonists broaden peptidoglycan recognition beyond NOD1/2, helping modulate gut microbiota and reduce GI inflammation.

Dual TrxR and DHFR inhibition by imidazolyl gold NHC compounds offers a targeted NSCLC treatment route with potent cytotoxicity.

A soluble VEGFR tyrosine kinase eye-drop formulation reaches posterior ocular tissues, avoiding frequent injections and lowering systemic toxicity.

Targeting NKB-expressing neurons in the nucleus accumbens reduces drug reward behavior by increasing signaling to the lateral hypothalamus.

A stabilized liquid nimodipine composition uses excipient and solvent ratios to limit degradation impurities while enabling higher-concentration dosing.

Novel heterocyclic compounds target LpxC to block lipid A biosynthesis and inhibit resistant gram-negative bacteria linked to pneumonia.

Alcohol-substituted imidazo[1,2-a]pyridines balance potent human NMT inhibition with improved cell permeability and metabolic stability.

Biomimetic HDL-like nanostructures improve nucleic acid uptake, avoid endosomal trapping, and enable targeted gene regulation with low toxicity.

A deep eutectic solvent keeps pharmaceutical agents liquid at ambient temperature without water, protecting sensitive compounds during delivery.

Non-canonical synthetic RNA enables DNA-free cell transfection and gene editing with lower toxicity, reduced mutation risk, and reliable expression.

C25 substituent changes in rifabutin analogs improve activity against M. abscessus, addressing weak efficacy of existing rifamycins.

Crystalline mesembrine salts and hydrates improve stability, dissolution consistency, and bioavailability for mental health therapies.

Mixed herbal extracts combined with docetaxel boost anticancer activity, suppress EGFR, and help address toxicity, resistance, and recurrence.

Dual EGFR and c-Met targeting with lazertinib plus amivantamab helps delay resistance in EGFR-mutant NSCLC while managing key adverse reactions.

Impedance sensing along an indwelling gastric tube tracks bolus passage to estimate stomach contents and guide safer enteral feeding decisions.

Indoline derivatives balance potent DDR1/DDR2 inhibition with lung retention and low systemic exposure for inhaled fibrosis treatment.

Combining testosterone with the Smoothened agonist SAG promotes oligodendrocyte formation and remyelination with a different path than immunomodulators.

Combining an anti-B7-H3 antibody-drug conjugate with ATR or ATM inhibitors boosts cancer cell suppression beyond single-agent therapy.

By binding inactive JAK2, 6-heteroaryloxy benzimidazole scaffolds avoid hyperphosphorylation resistance while improving potency and selectivity.

Novel Formula I antifungal compositions improve bioavailability and stability while treating azole- and echinocandin-resistant infections.

Linker-based ligand-drug conjugates improve tumor cell targeting and controlled cytotoxic release while limiting toxicity to normal cells.

A self-adhesive cytisine patch uses polymer matrices and a permeation enhancer to enable 24-hour delivery with fewer GI side effects.

Gi-biased piperidine ligands target MOP with KOP or NOP pathways to preserve analgesia while reducing opioid side effects.

A transfer-based whole blood process lowers residual amustaline after pathogen inactivation, enabling safer infusion without powered equipment.

A single C-peptide and bisphosphonate formulation targets bone loss and muscle wasting together to lower fracture risk in osteosarcopenia.

Selective THR-beta agonist compounds target liver metabolism to treat NASH and NAFLD while minimizing THR-alpha-linked cardiac and bone side effects.

Triazole-modified GalNAc linkers improve ASGPR binding and make oligonucleotide liver delivery more consistent through click-chemistry conjugation.

Novel piperazine cyclic ureas improve RIP1 inhibition while maintaining metabolic stability, helping block necroptosis and ferroptosis.

Selective 3α-hydroxy-17β-amide steroids target α4β3δ GABA A receptors to modulate brain excitability in CNS disorders.

Preloaded drug and diluent compartments mix on demand and inject in four steps, enabling reliable self-administration in emergencies.

Systematic substituent changes on imidazo[4,5-d]pyridazine create new TLR7/TLR8 agonists with flexible synthesis and cytokine induction.

BCN512 can be given before, during, or after radiation exposure to reduce fibrosis and support wound healing with prolonged tissue protection.

Selective deuteration of gamma-carbolines improves metabolic stability to treat residual psychosis symptoms with fewer off-target side effects.

Spirocyclic MAGL inhibitors use targeted ring and substituent changes to improve cellular activity and lipophilic efficiency.

Non-covalent heterocyclic crystals activate Nrf2 through Keap1 while reducing off-target protein interactions and heart failure risk.

Selective urea derivatives inhibit PI3Kα to suppress cancer growth while reducing wild-type pathway toxicity in normal tissues.

Co-administered bupropion inhibits dextromethorphan metabolism in extensive metabolizers, sustaining plasma levels with fewer doses.

Selective ALPK1 inhibition reduces pro-inflammatory cytokines and helps treat sepsis, cytokine storms, and related inflammation.

A bis-HCl tenapanor tablet with tartaric acid and propyl gallate improves dissolution across pH variation while maintaining stability.

A single-dose AAV2 vector with a modified capsid enables sustained aflibercept expression, reducing repeat eye injections and complications.

C25 piperazine and piperidine substitutions help rifabutin analogs overcome weak activity against non-tuberculous Mycobacteria, especially M. abscessus.

Mutation-selective pyrrolopyridinone compounds target EGFR exon 20 insertions and C797S while limiting wild-type EGFR activity and toxicity.

Dimethylglycine with amylopectin supports scalp metabolism and hair root strength to address hair loss with fewer side effects.

An osmogen, glidant, and granulated spray-dried dispersion prevent polymer gelation after water ingress, enabling faster capsule dissolution.

Single-stranded oligonucleotides target expanded CAG repeat RNA to improve splicing modulation, selectivity, affinity, and molecular stability.

By blocking BTK signaling, a fused pyrimidine compound reduces IgG and inflammatory cytokines to slow IgA nephropathy progression.

Defined EZH2 inhibitor crystal forms use XRPD and thermal fingerprints to improve stability and formulation consistency for cancer treatment.

Low-dose selective α-2 agonists induce sustained vasoconstriction while reducing rebound hyperemia, ischemia, and inflammatory sequelae.

Selective isoquinoline amides inhibit LRRK2 kinase to address disease progression beyond symptom relief in Parkinson's and related disorders.

Selective RIPK3 inhibition blocks necroptosis to reduce lung injury and inflammation while preserving apoptosis and virus clearance.

Small-molecule antagonists block endosomal TLR3/7/8/9 signaling to curb cytokine secretion and improve autoimmune disease treatment.

Corin/Lrtm1 marker selection and staged stem-cell culture improve dopaminergic progenitor purity while reducing lot variation and infection risk.

DNA demethylating pretreatment makes cancer cells more susceptible to γδ T cells, improving immune synapse formation and tumor lysis.

Small molecules bind HLA-DR to block autoantigen presentation to T cells, reducing immune activation and tissue damage in autoimmune disease.

Solid-supported catalysts produce oligosaccharide feed additives with controlled bond distribution, improving growth and feed efficiency without antibiotics.

A polysorbate-based liquid or lyophilized etoposide toniribate formulation maintains stability at 2-8°C or room temperature, easing storage and handling.

PEGylated menaquinol raises serum vitamin K and helps limit bone loss and tissue calcification in chronic kidney disease patients.

Low-dose colchicine with genetic screening helps prevent recurrent ischemic events after myocardial infarction while limiting GI risk.

Combining dexmedetomidine with midodrine promotes glymphatic flow while counteracting vascular effects that would otherwise impair brain clearance.

Targeted triazole modulators tune MRGPRD activity to improve selective treatment of pain and related disorders with low toxicity.

A faster-degrading polymer coating encapsulates a biodegradable metal scaffold to prevent fragment release and support absorption at the treatment site.

Selective BDII-targeting pyrrole and imidazole BET inhibitors reduce inflammation and fibrosis while avoiding corticosteroid-related side effects.

Diortho-substituted dihydroquinazolinones improve solubility and bioavailability while blocking retrograde transport used by intracellular toxins, viruses, and bacteria.

Inosine-supplemented cell expansion boosts CAR T effector function, anti-tumor activity, and memory/naïve cell populations.

RTEL1-targeting oligonucleotides reduce HBV cccDNA and pgRNA by destabilizing persistent viral DNA in chronic infection.

Selective αβ T cell depletion plus aminobisphosphonate and IL-15 activation boosts γδ T cell yield and purity from smaller blood samples.

Adding low-level ethanol and polyethylene glycol to a salbutamol HFA-152a inhaler composition improves aerosol stability and lung deposition over time.

Controlled crystallization of ST-246 polymorphs improves flow, compression, and formulation stability while managing crystalline form complexity.

A fused ring ADC conjugate uses targeted linkers to improve tumor-cell drug delivery, cytotoxicity, and therapeutic window.

A liposomal irinotecan regimen with 5-fluorouracil and leucovorin extends survival after gemcitabine failure while limiting toxicity.

Targeted glutaminyl cyclase inhibitors block glutamine and glutamate cyclization, suppressing harmful pGlu-Aβ peptide formation in Alzheimer's disease.

Self-assembled PEGylated bilirubin nanoparticles target inflamed tissue, remove ROS, suppress cytokines, and restore skin barrier function.

Small molecules redirect ATXN3 pre-mRNA splicing to lower full-length Ataxin-3 and help prevent toxic aggregates in SCA3.

Dissolution enhancer compounds help steviol glycosides dissolve faster in water, improving instant solubility for sweetener use.

Chemically modified SERPINC1-targeting dsRNA enables stable subcutaneous dosing to reduce bleeding in hemophilia with inhibitors.

Audiovisual responses, NLP scoring, and voice-face authentication reduce group differences while keeping online testing secure.

Candida lipase selectively converts cortexolone 17,21-diesters into stable 17α-monoesters, avoiding by-products and column chromatography.

A low-viscosity pasireotide formulation forms a liquid-crystalline depot in body fluids to reduce injection pain and avoid burst release.

Selective MC4R and GLP-1 agonist co-therapy improves weight loss and glucose tolerance while limiting side effects and short drug activity.

Topical Roseomonas mucosa and its exopolysaccharide curb B/T cell overactivation and inflammation while avoiding systemic side effects.

Titrated IV iloprost infusion improves blood flow in severe frostbite, helping reduce digit amputation risk while managing tolerability.

Ionic bonding with anionic polysaccharides stabilizes anthocyanin and improves antiviral activity against influenza A without conventional drug side effects.

Covalently scaffolded bicyclic peptides bind EphA2 with high selectivity, resist proteases, and lower bleeding risk in tumor-targeted drug delivery.

GalNAc-conjugated ApoCIII antisense oligonucleotides improve hepatocyte uptake, lower kidney exposure, and boost potency for metabolic and cardiovascular disease treatment.

A sustained-release ondansetron injection uses particle size and viscosity control to maintain antiemetic coverage for 2 to 10 days with fewer doses.

Group I intron self-splicing and IRES elements enable stable circRNA production for longer protein expression in eukaryotic cells.

Pretreated stem cells induced into migrating neuroblasts improve nerve regeneration and motor recovery after spinal cord injury.

A hydroxamic acid lipid blend improves nucleic acid delivery while limiting toxicity and aggregation through controlled lipid molar ratios.

Controlled carboxyalkylation gives chitosan broad pH solubility with lower immune response and better synovial fluid compatibility.

MCP-1 peptide micelles protect miR-145 from nuclease degradation and direct it to atherosclerotic plaques to limit off-target exposure.

Prodrug masking redirects 2-PMPA into kidneys and salivary glands, reducing PSMA therapy toxicity without blocking tumor uptake.

Novel quinazoline compounds tune PI3K isoform selectivity to improve therapeutic effect while addressing safety limits of existing inhibitors.

Targeted deuterium substitution in 4-phenyl-4-piperidinols lowers hERG and CYP inhibition, constipation risk, and metabolic instability.

Separate vitamin, trace element, lipid, amino acid, and carbohydrate chambers keep parenteral nutrition stable after heat sterilization.

Body-surface-area dosing and toxicity-guided adjustment help mirdametinib treat NF1-PN while limiting ocular, cardiac, and skin reactions.

Micronized crystalline API particles are FCA-coated by spray drying to cut cohesion, improving high-dose DPI aerosolization and stability.

These compounds target Nav 1.7 over other sodium channels to address potency, bioavailability, and side-effect limits in pain, cough, and itch treatments.

Subtype-selective compounds target S1P1 signaling without requiring a sub-maximal concentration of the natural ligand, limiting non-specific effects.

Targeted ALK2 binding inhibits aberrant BMP signaling to promote bone mineralization and growth while addressing treatment side effects.

A carboxylic acid-directed 1,4-dihydropyridine reduction produces predominantly trans CCR4 modulators instead of costly isomer mixtures.

Engineered bacteria release antiviral exosomes in the gut to suppress herpesvirus activity and reduce inflammation and microbiome dysbiosis.

A light-guiding spacer creates a reference region that separates sample absorption from holder interference in thin-layer measurements.

Chimeric heterocyclic polyamides selectively bind FXN GAA repeats to recruit regulatory molecules and modulate defective frataxin expression.

An alkaline component maintains pH 9.0–11.0, helping prevent GDTC hydrolysis while preserving heavy metal-removing efficacy during storage.

Crystallizing a protected NUC-3373 intermediate separates diastereoisomers before deprotection, improving purity and storage stability.

Compounds bind the MCV D4 processivity factor to block DNA synthesis and viral replication through topical or intradermal treatment.

Because lowering amyloid beta alone may not restore memory, mannose-targeted LNPs deliver miR-17 antagomirs to microglia and enhance autophagy.

HMPA replaces thyme as a high-safety active ingredient for food and drink compositions while activating parasympathetic nerves and supporting digestion.

Peri-ocular skin and meibomian glands form a sustained depot for lipophilic drugs, reducing corneal contamination and steroid-related risks.

Immediate and delayed releases distribute sleep-promoting, quality, recovery, and optional next-day agents to support overnight effectiveness.

Low physiological-pH solubility and intravenous hemolysis constrain NK1 antagonist use; the formula II prodrug improves solubility and prolongs release.

Green-light-responsive coumarin nanocarriers enable rapid, localized drug release with deeper ocular penetration and reduced phototoxicity.

Fisetin binds MERS-PLpro to inhibit proteolytic activity, offering a targeted approach to limit MERS-CoV replication and transmission.

CD73 inhibitor compounds reduce adenosine-driven immunosuppression and strengthen anti-tumor immune responses in cancer treatment.

Reactive-group masking helps deoxynucleoside prodrugs cross cell membranes and restore balanced nucleotide pools in mitochondrial disease.

Site-specific compounds inhibit H2O2 production at mitochondrial electron transport complexes, reducing ROS and supporting post-CPR cardiac function.

Axitinib and its analogs inhibit VEGF-PI3K-AKT signaling to restore Claudin-5/Occludin levels and reduce pathological blood-brain barrier permeability.

Deuterium substitution slows metabolic degradation in heterocyclic compounds, supporting arenavirus inhibition with reduced toxicity.

Low- and high-molecular-weight hyaluronic acid extend steroid presence in the tympanic cavity while limiting systemic side effects.

An incubated platelet or platelet-derivative composition counteracts antiplatelet effects to restore hemostasis before surgery.

Butyllithium and DMF enable moderate-temperature 5-PF synthesis, followed by amino acid functionalization for metabolic disease treatment.

Glucose, calcium, and magnesium help maintain physiological pH and osmolarity, supporting cell and tissue viability for 24–48 hours without replacement.

A defined benzenecarboxamide series addresses limited small-molecule IL-17A modulators for psoriasis and other inflammatory diseases.

Sub-micron emulsions address crude pomegranate oil’s low bioavailability by improving punicic acid stability and delivery.

Limited treatment effectiveness in lipid disorders motivates macrocyclic ACLY inhibitors that regulate cholesterol and fatty acid biosynthesis.

Intranasal saline baclofen offers a non-invasive alternative to intrathecal infusion, helping reach therapeutic concentrations with fewer complications.

Continuous SpO2 and motion sensing triggers integrated intramuscular naloxone delivery when overdose is detected, removing the need for a bystander.

Small-molecule allosteric inhibitors of GLS and GLS2 block coronavirus replication by targeting a host metabolic dependency shared across strains.

Selective PI3Kδ inhibition by pyrazolopyrimidine derivatives reduces B-cell activation and autoantibody secretion in immune disorders.

A one-pot diroximel fumarate route avoids intermediate isolation, reduces solvent use and production time, and reaches 76% overall yield.

Stable crystalline forms of a mutant BRAF degrader improve purity and reproducibility through XRPD, DSC, and TGA characterization.

To address late dosing, side effects, and resistance, plant-derived compounds inhibit coronavirus entry and replication.

Crystalline intermediate isolation replaces column chromatography in NAG-25 processing, reducing impurities, waste, and purification complexity.

Non-contact Raman monitoring replaces intrusive HPLC sampling to track blend uniformity in real time during inhalation powder manufacture.

The case uses MTAP deletion and MTA competition to make cancer cells selectively vulnerable to Formula I salts that inhibit PRMT5.

When macrophages lose phenotype, adhered polymeric particles deliver polarizing agents to sustain M1 or M2 activity.

Apcin-A and VHL ligands form a ternary complex that degrades Cdc20, arrests mitosis, and suppresses tumor growth.

Multiple cervical, thoracic, and lumbar sites target spinal networks, with adjustable frequency and amplitude to tune motor responses non-invasively.

A porous 3D-printed matrix packs up to 300 mg of droxidopa while saliva-driven disintegration remains within 30 seconds.

Specific hydrochloride and other quinazoline salt crystal forms target EGFRVIII inhibition while supporting blood-brain barrier penetration.

Skin permeability enhancers help epinephrine prodrugs cross biological membranes while supporting stable, localized topical delivery.

Converting a FAK inhibitor free base to an anhydrous tartrate salt reduces hygroscopicity and supports consistent solubility across pH ranges.

Defined substituents on a benzofuranyl hydroxyphenyl methanone core inhibit HSP47, reducing collagen deposition and inflammation in fibrosis models.

For patients resistant to conventional antihypertensives, A2-73 activates nitric oxide synthase and reduces systolic blood pressure by at least 3 mmHg.

Specific compounds induce stable IL-10 production in immune cells, reducing inflammation without increasing interleukin-6.

Inadequate UDCA response in PBC and PSC is addressed with Elafibranor, which reduces alkaline phosphatase and gamma-glutamyltransferase levels.

Sterically hindered bases suppress decomposition of alkyl fluoroalkyl sulfonates, resolving yield and impurity trade-offs in API synthesis.

Morpholino oligonucleotides bind pre-mRNA to induce exon skipping and restore the dystrophin reading frame.

siRNA agents targeting E2 and nsP1 genes reduce viral protein levels, addressing limited in vivo efficacy of prior therapies.

A metabolite panel measures kynurenine, arginine, sarcosine, and lysoPCs to diagnose COVID-19 infection.

A liposomal composition activates the innate immune system to provide short-term protection against respiratory pathogens.

Synthesized polyprenylated phloroglucinol derivatives act as potent P-glycoprotein inducers, addressing impaired amyloid-beta clearance in Alzheimer's disease.

Small molecule inhibitors disrupt oncogenic RAS-effector interactions, neutralizing tumor growth signals in proliferative disorders.

Low crosslinking cation exchange polymers reduce gastrointestinal side effects while maintaining effective potassium excretion.

SP6 RNA polymerase transcription of codon-optimized CFTR mRNA minimizes immune responses while ensuring high-yield production.

Segmented base editing components delivered via lipid nanoparticles durably reduce LDL-C and triglycerides, resolving chronic management complexity.

A synthesis process for piperazinyl-ethoxy-bromophenyl derivatives uses regioselective monobromination to produce high-purity compounds.

Immune cell carriers actively navigate to tumor sites, resolving the contradiction between drug delivery capability and targeting specificity.

Diethyl (2-cyanoethyl)phosphonate reduces inflammatory symptoms while minimizing adverse reactions associated with conventional NSAIDs.

Formula I derivatives resolve efficacy versus side effect contradictions by achieving precise TAAR1 binding affinity.

Gut microbiota and metabolites reduce regulatory T cell infiltration and inhibit IDO1 expression, overcoming drug resistance in colorectal cancer treatment.

Silicone-polyether copolymer composition with oxamide linkages achieves strong adhesion without thermal curing, preserving active agents.

Ion exchange and pH control separate diastereomers, eliminating expensive column costs.

A liposomal formulation merges celecoxib and plumbagin to inhibit melanoma cell proliferation.

Lurasidone addresses core autism symptoms while managing peripheral irritability through multi-functional receptor binding.

Aza-indazole compounds replace invasive surgery by inducing scleraxis gene expression, restoring tendon strength without complex mechanical intervention.

Targeted RNA interference lowers tau protein concentrations in GABAergic interneurons, addressing cognitive decline linked to apoE4 alleles.

Inhalation method bypasses gastrointestinal limitations to increase blood levels of vitamin B12 within minutes.

Crystalline pharmaceutical forms of Formula I achieve rapid systemic clearance, reducing unwanted side effects from slow inhibitor elimination.

IGFBPL1 mediates IGF-1 signaling to reverse developmental loss of axon regenerative capacity.

Myeloid-specific promoters restrict viral vector activity to microglia, preventing neuronal toxicity and oncogenic risks.

Phosphinate linkers prevent protein aggregation during antibody conjugation, resolving yield limits from hydrophobic interactions.

A polyphenol composition adjusts flavonol ratios to reduce harshness while maintaining antioxidant activity.

Segmented molecular structures optimize binding affinity while maintaining synthetic accessibility.

Cyclic Prolyl Glycine promotes neurogenesis via intracellular signaling modulation, addressing inadequate disease progression control in current therapies.